


Asselah T, Reesink H, Gerstoft J, et al. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype


Beste LA, Green PK, Berry K, Kogut MJ, Allison SK, Ioannou GN. Effectiveness of hepatitis C antiviral treatment in a USA


Cotter TG, Paul S, Sandikci B, et al. Increasing utilization and excellent initial outcomes following liver transplant of hepatitis C virus (HCV)-viremic donors into HCV-negative recipients: outcomes following liver transplant of HCV-viremic...


German P, Pang P, West S, Han LL, Sajwani K, Mathias A. Drug interactions between direct acting anti-HCV antivirals sofosbuvir and ledipasvir and HIV antiretrovirals [abstract 06]. Presented at 15th International Workshop on Clinical
Pharmacology of HIV and Hepatitis Therapy; May 19-21; Washington DC. 2014;


Götz HM, van Doornum G, Niesters HG, Hollander JGden, Thio HB, de Zwart O. A cluster of acute hepatitis C virus infection among men who have sex with men--results from contact tracing and public health implications. AIDS.


Lange B, Roberts T, Cohn J. Diagnostic accuracy of detection and quantification of HBV-DNA and HCV-RNA using dried blood spot (DBS) samples - a systematic review and meta-analysis. BMC Infect Dis. 2017;17(Suppl 1):693.


Lawitz EJ, Gane EJ, Pearlman B, et al. Efficacy and safety of 12 wks vs 18 wks of treatment w/ GRZ and ELB w/ or without RBV for HCV GT1 infection in previously untreated pts w/ cirrhosis and pts w/ previous null response w/ or without cirrhosis (C-WORTHY), randomised, open-label phase 2 trial. Lancet. 2015;385(9973):1075-1086.


Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for


Maurer K, Gondles EF, Efeti D, Strom HV, Strom HV. Hepatitis C in correctional settings: challenges and opportunities. 2015;


Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic...
Morgan RL, Baack B, Smith BD, Yartel A, Pitsi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the


Morrill JA, Shrestha M, Grant RW. Barriers to the treatment of hepatitis C. Patient, provider, and system factors. J Gen

Mosley JW, Operskalski EA, Tobler LH, et al. The course of hepatitis C viraemia in transfusion recipients prior to

Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4,


Moyer VA. Screening for hepatitis C virus infection in adults: US Preventive Services Task Force recommendation

Mücke MM, Backus LI, Mücke VT. Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a

Murphy SM, Dweik D, McPherson S, Roll JM. Association between hepatitis C virus and opioid use while in

Murray KF, Balistreri WF, Bansal S, et al. Safety and efficacy of ledipasvir-sofosbuvir with or without ribavirin for chronic

Musso G, Gambino R, Cassader M, Pagano G. A meta-analysis of randomized trials for the treatment of nonalcoholic fatty

are effective in reducing risk of HIV transmission among people living with HIV: results from the Health Resources and
Services Administration (HRSA)'s special projects of national significance initiative. AIDS Behav. 2010;14(3):483-492.

Naganuma A, Chayama K, Notsumata K, et al. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and
overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol.


Nazario HE, Ndungu M, Modi AA. Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with endstage renal disease on haemodialysis or GFR


Neate R. Welcome to Jail Inc: how private companies make money off US prisons. The Guardian. 2016;.


Newsum AM, Stolte IG, van der Meer JTM. Development and validation of the HCV-MOSAIC risk score to assist testing for acute hepatitis C virus (HCV) infection in HIV-infected men who have sex with men (MSM). Euro Surveill. 2017;22(21):30540.


Pearlman B, Perrys M, Hinds A. Sofosbuvir/velpatasvir/voxilaprevir for previous treatment failures with


Poordad F, Pol S, Asatryan A, et al. MAGELLAN-1, part 2: glecaprevir and pibrentasvir for 12 or 16 weeks in patients with...


Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to
Rosenthal P, Schwarz KB, Gonzalez-Peralta RP, et al. Sofosbuvir and ribavirin therapy for children aged 3 to


Schwarz KB, Rosenthal P, Murray KF, et al. Ledipasvir-sofosbuvir for 12 weeks in children 3 to


Selph S, Chou R. Impact of contacting study authors on systematic review conclusions: diagnostic tests for hepatic fibrosis. 2014.


Shelton BA, Sawinski D, Mehta S, Reed RD, MacLennan PA, Locke JE. Kidney transplantation and waitlist mortality rates among candidates registered as willing to accept a hepatitis C infected kidney. Transpl Infect Dis. 2018;20:e12829.


Thorpe J, Saeed S, Moodie EE, Klein MB. Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection. AIDS. 2011;25(7):967-975.


Prescription drug pricing in the private sector. 2015.


Varan AK, Mercer DW, Stein MS, Spaulding AC. Hepatitis C seroprevalence among prison inmates since 2001: still high


Wyles D, Bräu N, Kotttilil S, Daar ES, Ruane P, Workowski K, et al.. Sofosbuvir and velpatasvir for the treatment of HCV in


